30 results about "Lipid vesicle" patented technology

The invention relates to the technical field of biology, and particularly discloses an acoustic fluid device and a method for controlling fusion of lipid vesicles through the acoustic fluid device, the device comprises a glass chamber and piezoelectric ceramics attached to the bottom face of the glass chamber, the piezoelectric ceramics are used for generating ultrasonic waves, and the glass chamber serves as a reaction chamber for fusing the lipid vesicles. The method comprises the following steps: determining a lipid vesicle fusion type, and determining vibration frequency and vibration intensity of required ultrasonic waves according to the type; and the piezoelectric ceramics generate ultrasonic waves with required vibration frequency and vibration intensity to act on the glass chamber. According to the invention, the intensity of the sound stream can be randomly and dynamically adjusted, so that the ultrasonic pulse is utilized to induce the sound stream to control the fusion of the lipid vesicles in a non-invasive manner. The method has the advantages of no toxicity, no chemical reagent residue, simple device, no special requirements on the physical properties of the fluid medium and the lipid membrane, non-contact control, good universality, no requirements on the bioprotein receptor on the surface of the lipid membrane and the components of the lipid membrane, and good biocompatibility.

The invention provides a membrane-wrapped organelle-like system for directionally assembling membrane protein, which comprises a molecular framework and a closed lipid bilayer membrane wrapping the outer side of the molecular framework, the molecular framework is loaded with load molecules, the molecular framework directionally recombines the lipid bilayer membrane through a transmembrane region of the membrane protein, and the lipid bilayer membrane is loaded with the load molecules. The lipid bilayer membrane provides a barrier and protection for a molecular framework and loaded molecules, and the lipid bilayer membrane is provided with directional recognition molecules. According to the invention, a molecular framework wrapped by a lipid bilayer membrane is utilized, and a novel technology capable of simulating lipid vesicles of an organelle membrane framework is adopted, so that a brand-new directional delivery function on specific cells or specific organelles in the specific cells can be endowed. And oriented assembly of a membrane protein compound and effective loading of bioactive molecules are realized by using a process of chemically recombining the lipid bilayer membrane.

This application relates to a biphasic lipid vesicle pharmaceutical composition comprising a lipid bilayer comprising vesicle-forming lipids, an oil-in-water emulsion stabilized by one or more surfactants, one or more compounds, and one or more penetration enhancers. The one or more penetration enhancers include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or in combination with one or more penetration enhancers selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants, and combinations thereof. This application also relates to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer, the biphasic lipid vesicle comprising a vesicle-forming lipid, an oil-in-water emulsion stabilized by one or more polycationic surfactants, and one or more compounds.

The present disclosure relates to compositions comprising phospholipids, lipid vesicles, and / or liposomes, and methods of use thereof. In one aspect, the present disclosure relates to methods and compositions for delivery of, biologically active lipids to reduce microvascular dysfunction and infarct size during revascularization of the blocked artery in a mammalian subject.

The invention relates to the technical field of lipid vesicle preparation, and particularly discloses size and position controllable lipid vesicle preparation equipment and method.The equipment comprises a cavity, a microarray structure and an ultrasonic transducer which are arranged hierarchically; the cavity is used for being filled with a physiological buffer solution; the surface of the microarray structure is provided with micropores with set sizes and positions, and lipid membranes are arranged in the micropores; the ultrasonic transducer emits ultrasonic waves to the microarray structure, the ultrasonic waves induce an array acoustic flow field through the micropore array structure of the microarray structure, and lipid membranes in micropores form spherical lipid vesicles under the combined action of Reynolds stress and the array acoustic flow field. According to the method, lipid vesicle preparation equipment is used for generating an array acoustic flow field to prepare the spherical lipid vesicles. According to the invention, inhibition of sodium chloride in a physiological buffer solution on lipid membrane expansion is broken through, the spherical lipid vesicles with controllable positions and sizes are prepared, and the spherical lipid vesicles are suitable for various lipid membranes.

The present invention provides methods of introducing a molecule of interest into a lipid vesicle, such as an extracellular vesicle. The present invention provides lipid vesicles (e.g., extracellular vesicles) obtained using a method for introducing a molecule of interest into lipid vesicles (e.g., extracellular vesicles). According to the present invention, a complex of a lipid (e.g., an ionic lipid, in particular a liquid lipid composition) and a molecule of interest (a first complex) is fused with a lipid vesicle (e.g., an extracellular vesicle) to form a complex (a second complex). The first complex and the second complex are suitable for introducing a target molecule into a cell, and the second complex is particularly suitable for introducing a target molecule into a cell. The target molecule may be a protein (e.g., an antibody), a nucleic acid, or other compound.

The application belongs to the technical field of medicine, and particularly relates to an anti-HPV earthworm extract delivery body gel and a preparation method and application thereof. The preparation method comprises the following steps: stirring and hydrating earthworm extract and a lipid layer to obtain lipid vesicles, then performing inflation, ultrasonic treatment and extrusion to obtain earthworm extract delivery bodies, and finally adding a carbomer after adjusting pH and uniformly mixing to obtain the anti-HPV earthworm extract delivery body gel. The application improves the inhibitory effect on HPV viruses by compounding the carbomer gel with the earthworm extract delivery body, can promote the shrinkage and death of cervical cancer cells, further improves the viscosity of the earthworm extract delivery body by combining the gel with the earthworm extract delivery body, improves the adhesion of the earthworm extract delivery body and the inner wall of the vagina, and thus improves the effect of preventing and treating HPV virus infection.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

The invention belongs to the technical field of plant genetic transformation, and discloses a liposome-mediated maize pollen transfection method. The method comprises the following steps: preparing a plasmid DNA solution and a mixed lipid vesicle SMV solution composed of lecithin and cationic lipid DOTMA, and mixing and incubating the plasmid DNA solution and the mixed lipid vesicle SMV solution according to a mass ratio to form an SMV-DNA compound transfection solution; collecting and pretreating fresh corn pollen, and co-incubating with the transfection solution at low temperature; after drying treatment, the pollen is directly used for pollinating female ears of receptor corn, and transgenic offspring seeds are obtained. According to the method, efficient delivery of exogenous DNA is realized by utilizing affinity and electrostatic interaction of liposome and pollen cell membranes, tissue culture is not needed, the method is independent of genotypes, the method is simple and convenient to operate and low in cost, the problem of somatic cell variation is effectively avoided, the transformation efficiency can reach about 1.4%, and an efficient and practical new technical approach is provided for corn genetic improvement.

Cosmetic composition containing a vesicular concentrate consisting of a water solution of vegetal or of vegetal origin lipid vesicles with walls comprising phospholipids, phytosfingosine, phytosterol, beta-phytosteryl sulfate and optionally other derivatives of phytosterol and ceramides and / or pseudoceramides used for preparing cosmetic products for skin and hair care and for decorating face, eyes, eyelashes, lips and body. Said vesicular concentrate can also comprise a lysophospholipid, ester of phytosterol, fatty acids, humectants, emollients, active lipophilic molecules, active hydrophilic molecules, thickening agents, and film-forming molecules. The cosmetic product contains said vesicular concentrate cosmetic composition and any other cosmetically acceptable ingredient.

A method of inhibiting or reducing the migratory ability of tumour cells in a subject is provided. The method involves administering to the subject a composition including Cripto-positive lipid vesicles, the Cripto protein being displayed on the surface of the Cripto-positive lipid vesicles.

Hair treatment compositions are disclosed. In some embodiments, the composition can include a first fraction of lipid vesicles encapsulating a first material and a second fraction of lipid vesicles encapsulating a second, different material. In some embodiments, the first material is a stimulant material, such as caffeine or green tea catechins, and the second material is a botanical bioactive material. The lipid vesicles can be plant-derived extracellular vesicles. In some embodiments, the composition comprises a base material with a non-encapsulated stimulant material and lipid vesicles that encapsulate a botanical bioactive material. The composition can also include three distinct carrier systems: lipid vesicles, liposomes, and ceramide complexes, each encapsulating a different bioactive material. These compositions can be formulated into products such as serums, masks, shampoos, or conditioners, which can be part of a multi-product hair care system.

The invention relates to a composition for oral or topical human administration and a preparation method thereof. The present invention relates to pentacyclic triterpenoid compounds wherein said triterpenoid compounds are incorporated into lipid vesicles, preferably cream globules, surrounded by three layers of membranes. The triterpenoid is preferably betulinic acid, and / or betulinol, and / or lupenol, and / or oleanolic acid, and / or ursolic acid, most preferably betulinic acid. The incorporation of the triterpenoid compound into the milk fat globules or lipid vesicles at a high payload of at least 10 to at most 50 mg / ml is preferably accomplished with high energy emulsification techniques, most preferably ultrasound treatment. The composition is present as a liquid emulsion formulation in a preferred embodiment. In another preferred embodiment, the composition is a powder, which can be prepared from a liquid embodiment of the composition by, for example, spray drying or freeze drying techniques. The composition can be preferably used as a medicament, a food supplement or a nutraceuticals for the treatment or prevention of cancer, type 2 diabetes, obesity and cardiovascular diseases.

This invention discloses a method for modifying lipid vesicles with an amphiphilic polymer containing N-oxide teramine groups. The amphiphilic polymer is OPDEA-PCL. OPDEA-PCL is used to modify synthetic liposomes, yielding amphiphilic polymer-synthetic liposome nanoparticles. OPDEA-PCL is also used to modify natural exosomes, yielding amphiphilic polymer-exosome nanoparticles. The amphiphilic polymer-synthetic liposomes of this invention possess active liver and lung targeting functions. This invention, through the engineered modification of exosomes with OPDEA-PCL, accurately guides exosomes to the liver regions requiring treatment, thereby enhancing the repair effect of exosomes on liver ischemia-reperfusion injury.

The invention relates to nanoparticles, nano eye drops as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a nanoparticle. The nanoparticle is composed of a tyrosine kinase inhibitor and a carrier protein, the mass ratio of the tyrosine kinase inhibitor to the carrier protein is (2-4): 1. The tyrosine kinase inhibitor-loaded nanoparticles are prepared and creatively combined with the photosensitizer-loaded lipid vesicles to obtain the synergistic photodynamic-VEGF inhibition difunctional photoresponsive nano eye drops which are uniform in particle size, simple and feasible in preparation method and good in stability; the photosensitizer and tyrosine kinase inhibitor co-delivery hydrogel prepared by the method realizes efficient co-delivery of the photosensitizer and the tyrosine kinase inhibitor, has a laser response release behavior, can be detained in eye tissues for a long time, not only greatly improves the bioavailability of hydrophobic drugs, but also realizes the final curative effect of resisting ocular angiogenesis, and has potential clinical application value.

The present invention is directed to formulations comprising a water-immiscible fluorocarbon solvent and at least one amphiphilic polymer, wherein the least one amphiphilic polymer is selected from a diblock co-polymer surfactant of formula A-B and a triblock co-polymer surfactant of formula B'-A'-B', wherein A and A' independently of each other represent a water-soluble polymer block having a weight average molecular weight in the range of 300 g / mol to 2000 g / mol, and B and B' represent independently of each other a perfluorinated polyether block having a weight average molecular weight in the range of 1500 g / mol to 7500 g / mol. Said formulations exhibit improved properties which render them particularly useful in droplet-based microfluidics applications, including the construction of lipid vesicles, cell encapsulation and monitoring, and droplet digital molecular biology.

The present application relates to a squeezing preparation method of the Caesalpinia minax lipid vesicle-like nanoparticles, comprising the following steps: mixing Caesalpinia minax and ultrapure water with a mass ratio of 1:6-1:10 to squeeze juice, then extruding the juice through a 100-200 mesh filter to obtain a Caesalpinia minax raw solution; then, gradient centrifuging the Caesalpinia minax raw solution to obtain a supernatant; finally, centrifuging the supernatant at a relative centrifugal force higher than the highest relative centrifugal force of the gradient centrifuging, then adding a standard phosphate buffer with a mass ratio of 1:8-1:10 to resuspend and precipitate, thereby obtaining the Caesalpinia minax lipid vesicle-like nanoparticles. The present application also provides the Caesalpinia minax lipid vesicle-like nanoparticles obtained by the method and the application of the Caesalpinia minax lipid vesicle-like nanoparticles in the treatment of ulcerative colitis. The present application overcomes the seasonal influence of the preparation of the existing tea lipid vesicle-like nanoparticles, greatly reduces the cost and controls the purity and quality, can solve the intestinal ecological imbalance problems such as mucosal epithelial repair and barrier homeostasis, has good safety and does not produce side effects, and is also a potential treatment for gastrointestinal disease treatment.

The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

The present invention relates to an exosome-like nanovesicle for gene delivery and a method for preparing the same. The exosome-like nanovesicle comprises a lipid phase and an inner aqueous phase encapsulated within the lipid phase. The raw materials for preparing the lipid phase include cholesterol, phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine, and sphingomyelin; the inner aqueous phase contains a nucleic acid drug. The present invention arranges the raw material components of the lipid phase, avoiding the use of cationic lipids and ionizable lipids, thereby preparing anionic lipid vesicles that mimic the lipid components of exosomes. The lipid phase encapsulates the inner aqueous phase containing the nucleic acid drug, and the exosome-like nanovesicles have the characteristics of good stability, low toxicity, and high transfection efficiency. Not only do they have the advantages of natural exosomes with limited immunogenicity, high delivery efficiency, and enhanced stability during in vivo circulation, but the preparation process and final quality are controllable, making commercial production and clinical translation more easily achieved.

The invention discloses lipid vesicles co-loading salvia miltiorrhiza-radix puerariae effective components, a preparation method and application, and the preparation method comprises the following steps: placing egg yolk lecithin, sodium deoxycholate, radix puerariae isoflavone, tanshinone and salvianolic acid in a round-bottom flask according to a weight ratio of 50: (22-27): 10: (0.3-0.9): 7, then adding methanol for fully dissolving, carrying out rotary evaporation under the conditions of 40 DEG C and 50 rpm / min, filtering, washing, and drying to obtain the lipid vesicles. Removing methanol to obtain a film; performing vacuum drying overnight at room temperature to obtain a dry and transparent film framework; adding ultrapure water into the membrane skeleton, and carrying out hydration treatment to obtain a liposome solution; and filtering the liposome solution with a 0.22 [mu] m cellulose acetate membrane to obtain the liposome. Through multi-component synergistic encapsulation, strong hydrophobic tanshinone is encapsulated in a phospholipid bilayer, weak hydrophobic pueraria isoflavone is distributed on a phospholipid layer or interface, and hydrophilic salvianolic acid is contained in a water phase or interface, so that the stability of a lipid vesicle system is enhanced, and the problem of low bioavailability of a preparation is solved.

The present invention relates to a liposome composition comprising brillaroxazine incorporated into bilayer lipid vesicles. In one embodiment, the liposome composition comprises bilayer lipid vesicles encapsulating an aqueous solution, wherein the bilayer lipid vesicles contain one or more phospholipids, sterols, and brillaroxazine, and the aqueous solution contains maltodextrin. The present invention also relates to a pharmaceutical composition comprising a brillaroxazine liposome composition and a pharmaceutically acceptable carrier.

The invention relates to the technical field of medicine, and discloses a nuciferine-based nano preparation for targeting digestive tract tumors and a preparation method thereof.The nuciferine-based nano preparation for targeting digestive tract tumors comprises nuciferine, 1, 2-dipalmitoyl-sn-glycerol-3-phosphatidylcholine, cholesterol, cholesterol hemisuccinate, 1, 2-dipalmitoyl-sn-glycerol-3-phosphatidylcholine, cholesterol hemisuccinate, 1, 2-dipalmitoyl-sn-glycerol-3-phosphatidylcholine, cholesterol hemisuccinate, 1 the lipid vesicle is composed of 1, 2-dioleoyl-sn-glycerol-3-phosphatidyl ethanolamine and distearoyl phosphatidyl ethanolamine-polyethylene glycol (2000)-cyclo (essence-glycerol-radix asparagi-styrene-acrylic-lysine) polypeptide, and the lipid vesicle is composed of 2, 2-dioleoyl-sn-glycerol-3-phosphatidyl ethanolamine and distearoyl phosphatidyl ethanolamine-polyethylene glycol (2000)- The preparation method of the nuciferine-based digestive tract tumor targeting nano preparation comprises the steps of film dispersion, hydration, high-pressure extrusion and purification. The active targeting effect of the cyclo (essence-glycerol-asparagi-styrene-acrylic-lysine) polypeptide ligand is utilized. Synergistic release of drugs in a tumor microenvironment is achieved, the targeting efficiency and local drug concentration of nuciferine are improved, and the anti-tumor effect is enhanced.

The application relates to the field of biological medicines, and specifically discloses amphotericin B liposomes and a preparation method thereof. The preparation method comprises the following steps: S1, mixing amphotericin B, liposome raw materials and an organic solvent to obtain a mixed solution; S2, shearing the mixed solution and a freeze-drying protection solution to form a lipid vesicle, then performing pre-freezing treatment, and then performing low-pressure freeze-drying to obtain a raw material powder; and S3, dissolving, hydrating, homogenously extruding, filtering and freeze-drying the raw material powder in the step S2 to obtain the amphotericin B liposomes. The application also discloses the amphotericin B liposomes prepared by the above method. The application has the characteristics that the removal of the organic solvent does not affect the stability of the medicine, and the obtained amphotericin B liposomes have a higher encapsulation rate.

The present disclosure relates to compounds of Formula (I) and their methods of use thereof. The compounds of Formula (I) are conjugated oligoelectrolytes and are suitable for use as a membrane probe to label and / or detect cells and / or lipid vesicles and thus in flow cytometry applications. The present disclosure also relates to a flow system for detecting and / or quantifying cells and / or lipid vesicles.

The present invention is directed to a liposome composition comprising brilaroxazine incorporated in bilayer lipid vesicles. In one embodiment, the liposome composition comprises bilayer lipid vesicles encapsulating an aqueous solution, wherein the bilayer lipid vesicles comprise one or more phospholipids, sterol, and brilaroxazine, and the aqueous solution comprises maltodextrin. The present invention is also directed to a pharmaceutical composition comprising the brilaroxazine liposome composition and a pharmaceutically acceptable carrier.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical preparation for improving premature ovarian failure and a preparation method thereof. The pharmaceutical preparation comprises the following raw materials in parts by weight: drug-loaded lipid vesicles 10-30 parts, cell membrane suspension 2000 parts, and freeze-drying protective agent 10 parts. The responsive inner core is constructed by cross-linking natural polysaccharide and thioether diamine, and efficiently loads rh-bFGF. The fusion membrane is constructed by the liposome modified with FSHB targeting peptide and the ovary granulosa cell membrane, and realizes the coating of melatonin. The fusion membrane has homologous and active double targeting capabilities, can intelligently depolymerize and release drugs under the local high oxidative stress microenvironment of the ovary, and can efficiently and safely improve and repair the damaged ovarian function through the multi-dimensional synergistic effect of ROS clearance, natural polysaccharide activity and microvascular regeneration promotion.

The present invention relates to a liposome composition comprising bulaxacin incorporated in a bilayer lipid vesicle. In one embodiment, a liposome composition comprises bilayer lipid vesicles encapsulating an aqueous solution wherein the bilayer lipid vesicles comprise one or more phospholipids, sterols, and bulaxacin, and the aqueous solution comprises maltodextrin. The invention also relates to a pharmaceutical composition comprising the bulaxacin liposome composition and a pharmaceutically acceptable carrier.

To provide a method for delivering a compound to the skin of a subject.SOLUTION: A method for delivering a compound to the skin of a subject includes topically applying an effective dose of one or more biphasic lipid vesicles to the skin of the subject, where the biphasic lipid vesicle contains one or more infiltration accelerators including (i) the compound and (ii) one or more nonionic detergents having approximately 10 or less of hydrophilic-lipophilic balance (HLB), and the one or more nonionic detergents having approximately 10 or less of HLB contains dimonomethylether oleyl ether, sorbitan monopalmitate, or polyoxyethylene (4) dilaurate.SELECTED DRAWING: Figure 1A-1

The present application relates to a kind of nanoparticles, nano drop eye drops and its preparation method and application, belong to medical technology field.The present application provides a kind of nanoparticle, the nanoparticle is composed of tyrosine kinase inhibitor and carrier protein;The mass ratio of tyrosine kinase inhibitor and carrier protein is 2~4:1.The present application prepares a kind of nanoparticle loaded tyrosine kinase inhibitor, creatively combines it with light-sensitive agent loaded lipid vesicle, obtains a kind of synergistic photodynamic-VEGF inhibits bifunctional light-responsive nano drop eye drops, its particle size is uniform, preparation method is simple and easy to operate, and stability is good, realizes the efficient co-delivery of light-sensitive agent, tyrosine kinase inhibitor, with laser response release behavior, and can be long time in eye tissue Retention, not only greatly improve the bioavailability of hydrophobic drug, and realize the final curative effect of anti-ocular angiogenesis, with potential clinical application value.